Tags : Daewon Pharmaceutical

Biosimilars Insights+

Insights+ Key Biosimilars Events of May 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Fresenius Kabi expanded its footprints with the acceptance of MAA and BLA of its MSB11455 (biosimilar, pegfilgrastim) in the EU and the US respectively, and also signed an agreement with Medec to commercialize Idacio (adalimumab, biosimilar) in […]Read More

Biosimilars

Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis

Shots: Terrosa is a parathyroid hormone (PTH) gene recombination candidate originally developed by Richter-Helm Biotec to treat osteoporosis in men and postmenopausal women including those at high risk of fracture. Additionally, Terrosa has completed its P-I and P-III trials in EU and Japan has shown an increase in bone density in the spine, femur, and […]Read More